Synthesis and Antibacterial Activity of 3-(Substituted arylmethyl)-4-acylaminomethyloxazolidin-2-ones and Derivatization to Symmetrical Twin-Drug Type Molecules
Fumiko Fujisaki
Faculty of Pharmaceutical Sciences, Fukuoka University, Nanakuma, Jonan-ku, Fukuoka, 814-0180 Japan
Search for more papers by this authorSachi Hiromatsu
Faculty of Pharmaceutical Sciences, Fukuoka University, Nanakuma, Jonan-ku, Fukuoka, 814-0180 Japan
Search for more papers by this authorYumiko Matsumura
Faculty of Pharmaceutical Sciences, Fukuoka University, Nanakuma, Jonan-ku, Fukuoka, 814-0180 Japan
Search for more papers by this authorAki Fukami
Faculty of Pharmaceutical Sciences, Fukuoka University, Nanakuma, Jonan-ku, Fukuoka, 814-0180 Japan
Search for more papers by this authorNobuhiro Kashige
Faculty of Pharmaceutical Sciences, Fukuoka University, Nanakuma, Jonan-ku, Fukuoka, 814-0180 Japan
Search for more papers by this authorFumio Miake
Faculty of Pharmaceutical Sciences, Fukuoka University, Nanakuma, Jonan-ku, Fukuoka, 814-0180 Japan
Search for more papers by this authorCorresponding Author
Kunihiro Sumoto
Faculty of Pharmaceutical Sciences, Fukuoka University, Nanakuma, Jonan-ku, Fukuoka, 814-0180 Japan
E-mail: [email protected]Search for more papers by this authorFumiko Fujisaki
Faculty of Pharmaceutical Sciences, Fukuoka University, Nanakuma, Jonan-ku, Fukuoka, 814-0180 Japan
Search for more papers by this authorSachi Hiromatsu
Faculty of Pharmaceutical Sciences, Fukuoka University, Nanakuma, Jonan-ku, Fukuoka, 814-0180 Japan
Search for more papers by this authorYumiko Matsumura
Faculty of Pharmaceutical Sciences, Fukuoka University, Nanakuma, Jonan-ku, Fukuoka, 814-0180 Japan
Search for more papers by this authorAki Fukami
Faculty of Pharmaceutical Sciences, Fukuoka University, Nanakuma, Jonan-ku, Fukuoka, 814-0180 Japan
Search for more papers by this authorNobuhiro Kashige
Faculty of Pharmaceutical Sciences, Fukuoka University, Nanakuma, Jonan-ku, Fukuoka, 814-0180 Japan
Search for more papers by this authorFumio Miake
Faculty of Pharmaceutical Sciences, Fukuoka University, Nanakuma, Jonan-ku, Fukuoka, 814-0180 Japan
Search for more papers by this authorCorresponding Author
Kunihiro Sumoto
Faculty of Pharmaceutical Sciences, Fukuoka University, Nanakuma, Jonan-ku, Fukuoka, 814-0180 Japan
E-mail: [email protected]Search for more papers by this authorAbstract
In connection with our studies on antibacterial active compounds in the class of new oxazolidinones against Gram-positive (Staphylococcus aureus) and Gram-negative (Escherichia coli) strains, some molecular modifications were attempted. In this study, molecular modifications of 4-aminomethyloxazolidin-2-ones (3a) to the corresponding 4-acylaminomethyloxazolidin-2-one derivatives (3c–d) and preparations of the represented twin-drug type molecules (10–14) were investigated. Some additional 4-dialkylaminomethyloxazolidin-2-ones (2) were also synthesized. The synthesized compounds were evaluated for antibacterial activity with Gram-positive (S. aureus) and Gram-negative (E. coli) strains.
REFERENCES AND NOTES
- 1 Oshovsky, G. V.; Reinhoudt, D. N.; Verboom, W. Angew Chem Int Ed 2007, 46, 2366.
- 2 Imberty, A.; Varrot A. Curr Opin Struct Biol 2008, 18, 567.
- 3 Varki, A. Essentials of Glycobiology, 2nd ed.; Cold Spring Harbor Laboratory Press: Cold Spring Harbor, N. Y., 2009; pp 719–732.
- 4 Fujisaki, F.; Shoji, K.; Shimodouzono, M.; Kashige, N.; Miake, F.; Sumoto, K. Chem Pharm Bull 2010, 58, 1123.
- 5 Abe, N.; Fujisaki, F.; Sumoto, K. Chem Pharm Bull 1998, 46, 142.
- 6 Fujisaki, F.; Abe, N.; Sumoto, K. Chem Pharm Bull 2004, 52, 1238.
- 7 Fujisaki, F.; Abe, N.; Sumoto, K. Heterocycles 2008, 75, 1681.
- 8 Fujisaki, F.; Shoji, K.; Sumoto, K. Chem Pharm Bull 2009, 57, 1415.
- 9 Fujisaki, F.; Shoji, K.; Sumoto, K. Heterocycles 2009, 78, 213.
- 10These compounds (2) synthesized in this study showed weak antibacterial activities (MIC = 0.286–0.465 µM/mL) against E. coli but had no antibacterial activities against S. aureus (at the concentration of >0.286–0.465 µM/mL).
- 11Compounds (3c and 3d) showed antibacterial activities (MIC = 0.293 and 0.280 µM/mL, respectively) against E. coli and antibacterial activities (MIC > 0.293 and >0.280 µM/mL, respectively) against S. aureus. Regarding compounds 3a and 3b, we could not determine the precise MIC values against both strains (>0.395 and > 0.365 µM/mL, respectively). However, we confirmed antibacterial activity against both strains by calculating the number of readily observable colonies for compounds in agar culture medium. Compound 3a showed a higher level of bacterial static activity at the concentration of 5 µM than that of 3b at the concentration of 10 µM. Therefore, we used the derivative (3a and 3b) as a template for the scaffold of twin-drug type molecules.
- 12 Leach, K. L.; Swaney, S. M.; Colca, J. R.; McDonald, W. G.; Blinn, J. R.; Thomasco, L. M.; Gadwood, R. C.; Shinabarger, D.; Xiong, L.; Mankin, A. S. Mol Cell 2007, 26, 393.
- 13 Locke, J. B.; Finn, J.; Hilgers, M.; Morales, G.; Rahawi, S.; Kedar, G. C.; Picazo, J. J.; Im, W.; Shaw, K. J.; Stein, J. L. Antimicrob Agents Chemother 2010, 54, 5337 and related references cited therein.
- 14 Lemaire, S.; Tulkens, P. M.; Bambeke, F. V. Antimicrob Agents Chemother 2010, 54, 2540 and related references cited therein.
- 15 Balzarini, J. Antiviral Res 2006, 71, 237 and related references cited therein.
- 16 Bax, B. D.; Chan, P. F.; Eggleston, D. S.; Fosberry, A.; Gentry, D. R.; Gorrec, F.; Giordano, I.; Hann, M. M.; Hennessy, A.; Hibbs, M.; Huang, J.; Jones, E.; Jones, J.; Brown, K. K.; Lewis, C. J.; May, E. W.; Saunders, M. R.; Singh, O.; Spitzfaden, C. E.; Shen, C.; Shillings, A.; Theobald, A. J.; Wohlkonig, A.; Pearson, N. D.; Gwynn, M. N. Nature 2010, 466, 935.
- 17 Camille, G. W. The Practice of Medicinal Chemistry, 3rd ed.; Academic Press: San Diego, 2008.
- 18 Krishnamurthy, V. M.; Estroff, L. A.; Whitesides, G. M. Multivalency in ligand design. In Methods and Principles in Medicinal Chemistry: Fragment-based Approaches in Drug Discovery, R. Mannhold; H. Kubinyi; G. Folkers, Eds. WILEY-VCH Verlag GmbH & Co. KGaA: Weinheim, 2006, Vol 34, pp 11–53.
- 19We used a racemic 4-aminomethyloxazolidin-2-one (9) as a starting material in the synthesis of twin-drug type compounds. The obtained twin-drug type products (10–14) can be considered to be a mixture of three twin-drug type molecules, that is, a Cs-symmetrical meso compound and two enantiomeric C2-symmetrical molecules that have the same absolute configuration regarding two C-4-substituted oxazolidin-2-one rings in each molecule. For instance, three components in product 14a were detected by HPLC enantioseparation with the use of CHIRALPAK IA® as a chiral stationary phase. The obtained diastereomeric mixture exhibited very simple symmetrical 13C-NMR in DMSO-d6, showing little difference with respect to all of the signals assignable to substituted oxazolidin-2-one rings and a linker group. However, we found that the diastereomeric mixture of compound 14a exhibited significant differences in the 1H and 13C-NMR spectra in CDCl3 (see Experimental section). In the case of compounds 13a and 13b, 13C-NMR spectra indicated unsymmetrical molecular features. It is likely that intramolecular hydrogen bonding between pyridine ring nitrogen and one of the amide functionalities 25 gave rise to a slightly different non-equivalent magnetic resonance patterns.
- 20This result has considerable significance in comparison with antibacterial activity of cephalothin. Thus, when the experiments with E. coli NIHJ or S. aureus Terajima were carried out under similar conditions, antibacterial activity of cephalothin (MIC = 12.5 µg/mL (0.032 µM/mL) or 0.20 µg/mL (0.001 µM/mL), respectively) had been reported 26.
- 21 Japanese Society of Chemotherapy (1989). Chemotherapy 1990, 38, 102.
- 22 Japanese Society of Chemotherapy (1992). Chemotherapy 1993, 41, 184.
- 23This compound (8a) was easily obtained by the procedure described in our previous paper 7. Yield was 85.0%, mp 208–210°C. IR (KBr) cm−1: 1773, 1736, 1717. FABMS (positive) m/z: 413 (M + H)+. Anal. Calcd for C25H20N2O4: C, 72.80; H, 4.89; N, 6.79. Found: C, 72.87; H, 4.94; N, 6.83.
- 24This compound (8b) was prepared by the procedure reported previously 7. Yield was 61.4%, mp 196–199°C. IR (KBr) cm−1: 1772, 1736, 1713. FABMS (positive) m/z: 439 (M+). Anal. Calcd for C23H22N3O5F: C, 62.86; H, 5.05; N, 9.56. Found: C, 62.66; H, 5.26; N, 9.57.
- 25 Affeld, A.; Hübner, G. M.; Seel, C.; Schalley, C. A. Eur J Org Chem 2001, 2877.
- 26
Noto, T.;
Nehashi, T.;
Endo, H.;
Saito, S.;
Matsubara, S.;
Harada, S.;
Ogawa, H.;
Koyama, K. J Antibiot 1976, 19, 1058.
10.7164/antibiotics.29.1058 Google Scholar
